Answers are grounded in this paper and cite their sources.
Introduction: Circulating biomarkers that could complement histopathological and imaging assessment of metastatic pancreatic neuroendocrine neoplasms (PNENs) remain insufficiently characterized. This study evaluated serum tissue polypeptide-specific antigen/cytokeratin 18 (TPS/CY18) and cancer antigen 125 (CA125) in relation to hepatic metastases (HM) and regional or distant lymph-node metastases (LNM) in well-differentiated PNENs. Material and methods: This prospective, single-center study included 107 patients with well-differentiated PNENs: 60 with grade 1 neuroendocrine tumors (NET G1) and 47 with NET G2. The principal comparison was between patients with and without LNM and/or HM; skeletal and other distant metastases were not included in this definition. Biomarker concentrations were compared using the Mann–Whitney U test with Holm correction. Discriminatory performance was assessed using receiver operating characteristic curves, and factors associated with metastatic status were evaluated using multivariable logistic regression. Results: Lymph-node metastases and/or HM were present in 42 patients and absent in 65. Tissue polypeptide-specific antigen/cytokeratin 18 concentrations were numerically higher in patients with LNM/HM (median 79.96 vs. 51.64 U/L), but the difference was not significant (Holm-adjusted p = 0.140); the area under the curve (AUC) was 0.585 [95% confidence interval (CI) 0.469–0.700]. Median CA125 concentration was 6.95 vs. 5.16 U/mL (raw p = 0.042; Holm-adjusted p = 0.083), with an AUC of 0.617 (95% CI 0.502–0.726). After adjustment for age, sex, and grade, CA125 showed a weak association with LNM/HM [odds ratio (OR) per doubling 1.54; 95% CI 1.04–2.29; p = 0.032], whereas TPS/CY18 did not. Neuroendocrine tumor grade 2 was strongly associated with LNM/HM (OR 7.42; 95% CI 3.03–18.17; p < 0.001). Ki-67 and primary tumor size were independently associated with LNM and HM when analyzed separately, while neither biomarker independently contributed to the site-specific models. Conclusions: Cancer antigen 125 showed a weak and model-dependent association with LNM/HM but limited discriminatory performance. Tissue polypeptide-specific antigen/cytokeratin 18 provided no independent information. Tumor grade, Ki-67, and tumor size were more informative than the circulating biomarkers. These biomarkers should not replace histopathological or imaging assessment.
No takes yet. Share an insight, caveat, or question.
Rosiek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: